TNP-2198 (利福特尼唑)
Helicobacter pylori infection
Phase 3Completed (results published in The Lancet Infectious Diseases)
Key Facts
Indication
Helicobacter pylori infection
Phase
Phase 3
Status
Completed (results published in The Lancet Infectious Diseases)
Company
About TenNor Therapeutics
A clinical-stage Chinese biotech developing novel multi-target conjugate molecules for bacterial infections and metabolic diseases.
View full company profileTherapeutic Areas
Other Helicobacter pylori infection Drugs
| Drug | Company | Phase |
|---|---|---|
| HELIX | Lant Medical | Pre-clinical |
| Helicobacter pylori Treatment | OFD Biopharma | Commercial |
| Linaprazan Glurate | Cinclus Pharma | Unknown |
| JP-1366 | Livzon Pharmaceutical | IND |